Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Clinical trials on hydroxychloroquine/ chloroquine in COVID-19. Statement in response to damaging recent events

Clinical Trials Coronavirus COVID-19 General Research

On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.

Bacteria perform mass suicide to defend their colony

General Research

A new study from researchers at Oxford University’s Departments of Zoology and Biochemistry shows that warring bacteria will engage in suicidal attacks in vast numbers to take down competitors.

Oxford University’s COVID-19 vaccine: next steps towards broad and equitable global access

Clinical Trials Coronavirus COVID-19 General Research

The University of Oxford in partnership with AstraZeneca has taken the next steps in its commitment to broad and equitable global access to Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).

Brazilian Health Regulatory Agency approves trial of Oxford COVID-19 Vaccine

Clinical Trials Coronavirus COVID-19 General Research

On 2 June, the Brazilian Health Regulatory Agency (ANVISA) approved the inclusion of Brazil in the clinical trials conducted by Oxford University and supported by AstraZeneca, considering 2,000 volunteers to be tested in the country.

First patient recruited in key COVID-19 drug treatment trial

Clinical Trials Coronavirus COVID-19 General Research

A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.

New research finds half of UK parents uncomfortable with children returning to school

Coronavirus COVID-19 General Research

Half of UK parents do not feel comfortable about their children attending school following lockdown, according to early results from a new study asking parents and carers about their children’s mental health through the COVID-19 crisis.

Professor Fran Platt appointed as new Head of Department of Pharmacology

General

Professor Fran Platt has been appointed as the new Head of Department for Pharmacology at the University of Oxford. Fran took up her new post with effect from 1 June 2020 and will serve for an initial period of five years.

Eurofins Foundation and SENSE Foundation Brussels launch awards for students across the sciences

Awards and Appointments General

The University of Oxford is delighted to announce a joint gift from the Eurofins Foundation and SENSE Foundation Brussels to support students in the Medical Sciences and Mathematical, Physical and Life Sciences Divisions. The donation will lead to the creation of Eurofins Awards for undergraduate and postgraduate students, which will be granted over the course of the next three years.

First patient, a child, receives convalescent plasma through RECOVERY, the dedicated COVID-19 treatment trial

Clinical Trials Coronavirus COVID-19 General Research

The first person to be randomly selected to receive convalescent plasma through RECOVERY has now received a transfusion.

The Duke of Westminster donates £1m to Oxford University’s COVID-19 mental health research

Awards and Appointments Coronavirus COVID-19 General Research

Hugh Grosvenor, The Duke of Westminster, has donated £1m towards Oxford University’s COVID-19 mental health research programmes. This is part of the £10m donation announced by the Westminster Foundation last month to support the national COVID-19 relief effort.

COVID-19 drug trial could lead to enhanced respiratory care for patients

Clinical Trials Coronavirus COVID-19 General Research

Researchers at the University of Oxford are working with clinical collaborators from NHS hospitals to carry out a new clinical drug trial aimed at treating COVID-19, funded by LifeArc. It will test a drug that could raise oxygen levels in the blood in COVID-19 patients in order to improve their chances of recovery. Raising oxygen levels is important in COVID-19, because many patients with the disease die when oxygen levels in their arterial blood fall to levels that are too low to support life.

Virtual AIMday in the Microbiome - registration for academics now open

Events General

On Wednesday 1 July we are hosting an AIMday in the Microbiome, bringing academic and clinical excellence from across the University of Oxford together with industry to help answer the most pressing challenges in this area, as identified by industry.

HCQ with antibiotics to treat COVID-19 could be dangerous for the heart

Coronavirus COVID-19 General Research

Researchers from the Department of Physiology, Anatomy & Genetics (DPAG) have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.

The UK prepares for national launch of COVID-19 digital contact tracing app with the help of Oxford Scientists

Coronavirus COVID-19 General Research

The UK’s National Health Service (NHS) is finalising the release of a contact tracing app designed to slow the rate of infection for COVID-19. The tracing app, developed by the digital unit NHSx, is based on the evidence provided by a team of Oxford epidemiologists, mathematical modellers and ethicists in the Nuffield Department of Medicine, based at the Big Data Institute.

How has COVID-19 Impacted on People's Vulnerability to Mental Illness and Depression?

Coronavirus COVID-19 General Research

The Oxford University COSIE study (COvid-19, Social Isolation and Emotion) is an online study which asked people about their experiences during the coronavirus lockdown in late April 2020, while also using objective tests of psychological function to measure vulnerability to mental illness such as depression.

Conspiracy beliefs reduces the following of government coronavirus guidance

Coronavirus COVID-19 General Research

A new study from the University of Oxford shows that people who hold coronavirus conspiracy beliefs are less likely to comply with social distancing guidelines or take-up future vaccines.

Load More